Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Galardi

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Cancer Treatment Reviews|September 18, 2009
The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patientsCatherine Oakman, Erica Moretti, Francesca Galardi, et al.
Cancers|November 28, 2013
Significance of micrometastases: circulating tumor cells and disseminated tumor cells in early breast cancerCatherine Oakman, Marta Pestrin, Silvia Bessi, et al.
Breast Cancer Research : BCR|May 14, 2009
Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancerCatherine Oakman, Silvia Bessi, Elena Zafarana, et al.
Microbial Ecology|February 1, 2007
Isolation and characterization of endophytic bacteria from the nickel hyperaccumulator plant Alyssum bertoloniiRita Barzanti, Francesca Ozino, Marco Bazzicalupo, et al.
Cancers|March 28, 2014
Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?Natalie Turner, Marta Pestrin, Francesca Galardi, et al.
Pharmacological Research|February 28, 2016
Using CTCs for pharmacogenomic analysisChristopher D Hart, Francesca Galardi, Marta Pestrin, et al.
Breast (Edinburgh, Scotland)|October 22, 2011
Adjuvant systemic treatment for individual patients with triple negative breast cancerCatherine Oakman, Erica Moretti, Francesca Galardi, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|May 15, 2020
The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematologyMattia Altini, Nicola Gentili, William Balzi, et al.
Clinical Breast Cancer|December 23, 2020
A Dose-finding Study of Metronomic Oral Vinorelbine in Combination With Oral Cyclophosphamide and Bevacizumab in Patients With Advanced Breast CancerGiuseppina Sanna, Marta Pestrin, Erica Moretti, et al.
Environmental Pollution (Barking, Essex : 1987)|August 21, 2007
Arsenate tolerance in Silene paradoxa does not rely on phytochelatin-dependent sequestrationMiluscia Arnetoli, Riet Vooijs, Wilma ten Bookum, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Cancer Treatment Reviews|September 18, 2009
The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patientsCatherine Oakman, Erica Moretti, Francesca Galardi, et al.
Cancers|November 28, 2013
Significance of micrometastases: circulating tumor cells and disseminated tumor cells in early breast cancerCatherine Oakman, Marta Pestrin, Silvia Bessi, et al.
Breast Cancer Research : BCR|May 14, 2009
Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancerCatherine Oakman, Silvia Bessi, Elena Zafarana, et al.
Microbial Ecology|February 1, 2007
Isolation and characterization of endophytic bacteria from the nickel hyperaccumulator plant Alyssum bertoloniiRita Barzanti, Francesca Ozino, Marco Bazzicalupo, et al.
Cancers|March 28, 2014
Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?Natalie Turner, Marta Pestrin, Francesca Galardi, et al.
Pharmacological Research|February 28, 2016
Using CTCs for pharmacogenomic analysisChristopher D Hart, Francesca Galardi, Marta Pestrin, et al.
Breast (Edinburgh, Scotland)|October 22, 2011
Adjuvant systemic treatment for individual patients with triple negative breast cancerCatherine Oakman, Erica Moretti, Francesca Galardi, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|May 15, 2020
The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematologyMattia Altini, Nicola Gentili, William Balzi, et al.
Clinical Breast Cancer|December 23, 2020
A Dose-finding Study of Metronomic Oral Vinorelbine in Combination With Oral Cyclophosphamide and Bevacizumab in Patients With Advanced Breast CancerGiuseppina Sanna, Marta Pestrin, Erica Moretti, et al.
Environmental Pollution (Barking, Essex : 1987)|August 21, 2007
Arsenate tolerance in Silene paradoxa does not rely on phytochelatin-dependent sequestrationMiluscia Arnetoli, Riet Vooijs, Wilma ten Bookum, et al.
Pageof 4